PMID- 31932015
OWN - NLM
STAT- MEDLINE
DCOM- 20210921
LR  - 20210921
IS  - 1578-1275 (Electronic)
IS  - 0212-6567 (Print)
IS  - 0212-6567 (Linking)
VI  - 52
IP  - 7
DP  - 2020 Aug-Sep
TI  - Short-term mortality in end-stage heart failure patients.
PG  - 477-487
LID - S0212-6567(19)30060-5 [pii]
LID - 10.1016/j.aprim.2019.07.019 [doi]
AB  - OBJECTIVES: This study is aimed at analyzing the impact of the main factors 
      contributing to short and long-term mortality in patients at final stages of 
      heart failure (HF). SETTING: Patients attended at any of the 279 primary health 
      care centers belonging to the Institut Catala de la Salut, in Catalonia (Spain). 
      PARTICIPANTS: Patients with Advanced HF. DESIGN: Multicenter cohort study 
      including 1148 HF patients followed for one-year after reaching New York Heart 
      Association (NYHA) IV. MAIN MEASUREMENTS: The primary outcome was all-cause 
      mortality. Multivariate logistic regression models were performed to assess the 
      outcomes at 1, 3, 6, and 12 months. RESULTS: Mean age of patients was 82 (SD 9) 
      years and women represented 61.7%. A total of 135 (11.8%) and 397 (34.6%) 
      patients died three months and one year after inclusion, respectively. Male 
      gender, age, and decreased body mass index were associated with higher mortality 
      at three, six and twelve months. In addition, low systolic blood pressure levels, 
      severe reduction in glomerular filtration, malignancy, and higher doses of loop 
      diuretics were related to higher mortality from 6 to 12 months. The most 
      important risk factor over the whole period was presenting a body mass index 
      lower than 20kg/m(2) (three months OR 3.06, 95% CI: 1.58-5.92; six months OR 
      4.42, 95% CI: 2.08-9.38; and 12 months OR 3.68, 95% CI: 1.76-7.69). CONCLUSIONS: 
      We may conclude that male, age, and decreased body mass index determined higher 
      short-term mortality in NYHA IV. In addition, low systolic blood pressure, 
      reduced glomerular filtration, malignancy, and higher doses of loop diuretics 
      contribute to increasing the risk of mortality at medium and long-term. Such 
      variables are easily measurable and can help to decide the best way to face the 
      most advances stages of the disease.
CI  - Copyright (c) 2019 The Authors. Publicado por Elsevier Espana, S.L.U. All rights 
      reserved.
FAU - Verdu-Rotellar, Jose Maria
AU  - Verdu-Rotellar JM
AD  - Gerencia Atencion Primaria de Barcelona, Institut Catala de la Salut, Barcelona, 
      Spain; Primary Health Care University Research Institute Jordi Gol (IDIAPJGol), 
      Barcelona, Spain; School of Medicine, Universitat Autonoma de Barcelona, 
      Bellaterra, Spain.
FAU - Calero, Esther
AU  - Calero E
AD  - Primary Health Care University Research Institute Jordi Gol (IDIAPJGol), 
      Barcelona, Spain; Community Nursing, Preventive Medicine, Public Health and 
      History of Science Department, Faculty of Health Sciences, University of 
      Alicante, Spain; Hospital Universitari de Bellvitge, Institut Catala de la Salut, 
      L'Hospitalet de Llobregat, Barcelona, Spain.
FAU - Abellana, Rosa
AU  - Abellana R
AD  - Primary Health Care University Research Institute Jordi Gol (IDIAPJGol), 
      Barcelona, Spain; School of Medicine, Universitat de Barcelona, Barcelona, Spain.
FAU - Verdu-Soriano, Jose
AU  - Verdu-Soriano J
AD  - Community Nursing, Preventive Medicine, Public Health and History of Science 
      Department, Faculty of Health Sciences, University of Alicante, Spain.
FAU - Vinyoles, Ernest
AU  - Vinyoles E
AD  - Gerencia Atencion Primaria de Barcelona, Institut Catala de la Salut, Barcelona, 
      Spain; Primary Health Care University Research Institute Jordi Gol (IDIAPJGol), 
      Barcelona, Spain; School of Medicine, Universitat de Barcelona, Barcelona, Spain.
FAU - Del Val-Garcia, Jose Luis
AU  - Del Val-Garcia JL
AD  - Gerencia Atencion Primaria de Barcelona, Institut Catala de la Salut, Barcelona, 
      Spain; Primary Health Care University Research Institute Jordi Gol (IDIAPJGol), 
      Barcelona, Spain.
FAU - Domingo, Mar
AU  - Domingo M
AD  - Heart Failure Unit, Hospital Universitari Germans Trias i Pujol, Institut Catala 
      de la Salut, Badalona, Spain.
FAU - Munoz, Miguel-Angel
AU  - Munoz MA
AD  - Gerencia Atencion Primaria de Barcelona, Institut Catala de la Salut, Barcelona, 
      Spain; Primary Health Care University Research Institute Jordi Gol (IDIAPJGol), 
      Barcelona, Spain; School of Medicine, Universitat Autonoma de Barcelona, 
      Bellaterra, Spain. Electronic address: mamunoz.bcn.ics@gencat.cat.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20200110
PL  - Spain
TA  - Aten Primaria
JT  - Atencion primaria
JID - 9111075
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - *Angiotensin Receptor Antagonists
MH  - Angiotensin-Converting Enzyme Inhibitors
MH  - Cohort Studies
MH  - Female
MH  - *Heart Failure/mortality
MH  - Humans
MH  - Male
MH  - Risk Factors
PMC - PMC7393541
OTO - NOTNLM
OT  - End of life
OT  - Epidemiology
OT  - Epidemiologia
OT  - Factores pronosticos
OT  - Fin de vida
OT  - Heart failure
OT  - Insuficiencia cardiaca
OT  - Prognostic factors
EDAT- 2020/01/15 06:00
MHDA- 2021/09/22 06:00
PMCR- 2020/01/10
CRDT- 2020/01/15 06:00
PHST- 2019/01/29 00:00 [received]
PHST- 2019/07/08 00:00 [revised]
PHST- 2019/07/22 00:00 [accepted]
PHST- 2020/01/15 06:00 [pubmed]
PHST- 2021/09/22 06:00 [medline]
PHST- 2020/01/15 06:00 [entrez]
PHST- 2020/01/10 00:00 [pmc-release]
AID - S0212-6567(19)30060-5 [pii]
AID - 10.1016/j.aprim.2019.07.019 [doi]
PST - ppublish
SO  - Aten Primaria. 2020 Aug-Sep;52(7):477-487. doi: 10.1016/j.aprim.2019.07.019. Epub 
      2020 Jan 10.